Irish biopharma company Alkermes said that it has expanded an ongoing phase 1 trial for its immuno oncology drug ALKS 4230 to assess its safety and anti-tumor activity in combination with Merck’s PD-1 inhibitor KEYTRUDA (pembrolizumab) in advanced solid tumors. According to Alkermes, ALKS 4230 is an engineered fusion protein which selectively binds and signals […]
Continue reading …PvP Biologics initiates Kuma062 human trials for celiac disease treatment
September 8, 2018 No Comment
PvP Biologics, a US pharma company, has initiated two phase 1 clinical trials for Kuma062 to evaluate the recombinant enzyme for celiac disease treatment. According to PvP Biologics, Kuma062 has been designed to be active under acidic stomach conditions and it specifically targets the parts of gluten that are behind the autoimmune reaction causing celiac […]
Continue reading …
Israeli pharma company Compugen has dosed the first patient in the phase 1 clinical trial which is evaluating the company’s cancer immunotherapy antibody COM701 in patients with advanced solid tumors. COM701 has been designed to target the PVRIG gene, which according to the Israeli pharma company is a novel immune checkpoint target it had identified […]
Continue reading …
South Korean biotech company SillaJen and Hong Kong-based Lee’s Pharmaceutical have enrolled the first patient in China for a phase 3 trial called PHOCUS which will evaluate the oncolytic immunotherapy Pexa-Vec for the treatment of advanced liver cancer. The PHOCUS trial will aim to have 600 patients on board across the world who did not […]
Continue reading …Kodiak enrolls patients for retinal disease drug KSI-301’s phase 1 trial
September 2, 2018 No Comment
Clinical trial news : Kodiak Sciences has completed enrollment of patients for a phase 1 safety and tolerability study to evaluate its retinal disease drug KSI-301. The California-based biotech company, which is focused on developing therapies for retinal diseases, said that the phase 1 trial for KSI-301 being held in the US is an open […]
Continue reading …
Pfizer DMD drug update : US pharma giant Pfizer will scrap a couple of ongoing clinical trials evaluating its humanized monoclonal antibody domagrozumab (PF-06252616) for the treatment of Duchenne muscular dystrophy (DMD) owing to negative results. The two trials of the Pfizer DMD drug are B5161002 – a phase 2 safety and efficacy study and […]
Continue reading …Novartis’ heart failure drug Entresto can be initiated early in hospitalized patients
August 26, 2018 No Comment
Swiss drugmaker Novartis unveiled new data on Entresto (sacubitril/valsartan) from a phase 4 study which confirms that the heart failure drug can be initiated early and safely across a broad range of heart failure patients with reduced ejection fraction (HFrEF), whose condition has been stabilized following hospitalization because of an acute heart failure episode. In […]
Continue reading …
Clinical trial news : Alnylam Pharmaceuticals said that it has wrapped up enrollment of patients for a phase 3 trial called ENVISION for evaluating givosiran for the treatment of acute hepatic porphyrias (AHPs), a family of rare, genetic diseases. According to the US biopharma company, givosiran is an RNAi therapeutic that has been designed to […]
Continue reading …Teva, Regeneron report positive data for fasinumab in phase 3 osteoarthritis trial
August 19, 2018 No Comment
Teva Pharmaceutical Industries and Regeneron Pharmaceuticals said that a phase 3 study evaluating nerve growth factor (NGF) antibody fasinumab in patients with chronic pain from osteoarthritis (OA) of the knee or hip met both co-primary endpoints and all key secondary endpoints. According to the partners, fasinumab-treated patients had faced significantly less pain and had considerably […]
Continue reading …
Phase 3 trial for apomorphine infusion : British pharma company Britannia Pharmaceuticals said that its APO-go/MOVAPO (apomorphine) subcutaneous infusion has succeeded in a phase 3 trial called TOLEDO by delivering effective relief of persistent motor fluctuations in Parkinson’s disease. The TOLEDO trial saw apomorphine infusion given for 12 weeks in 107 Parkinson’s disease patients whose […]
Continue reading …
Business News Today
- Ant Financial, Vanguard create JV for investment advisory services in China
- IFF to acquire DuPont’s Nutrition & Biosciences in $26.2bn deal
- VetPartners to acquire National Veterinary Care for $168.5m
- JBS USA plans to acquire J&B Group meat processing facility in Pipestone
- Siemens Gamesa to acquire certain European assets of Senvion Group
- 3M to sell drug delivery business to Altaris Capital for $650m
- Constellation Brands, E. & J. Gallo Winery sign revised deal to address FTC concerns
- Nestlé to sell US ice cream business to Froneri for $4bn
- Vitol takes full ownership in asphalt trading business VALT
- Vitol signs deal with NLNG to buy Nigerian LNG from 2021
